Design of Phase II Cancer Trials for Evaluation of Cytostatic/Cytotoxic Agents

Research findings suggest that a new approach to evaluating cancer treatments may be more effective. In a report published in the Journal of Biopharmaceutical Statistics, scientists describe a design for Phase II clinical trials to assess both response and stable disease rates in patients with cancer. This approach could lead to a better understanding of the effectiveness of experimental anticancer agents.

Key Takeaways:

• The new approach to evaluating cancer treatments involves assessing both response and stable disease rates in patients with cancer.
• The design of the Phase II clinical trial described in the report uses a single-arm approach, where patients receive the experimental treatment and are evaluated for response and stable disease rates.
• The researchers used a restricted search algorithm to select the most suitable design for the trial, ensuring that the trial has sufficient statistical power to detect a difference in response rates.
• The trial design incorporates an early stopping rule for lack of efficacy, allowing researchers to stop the trial early if the treatment is not effective.
• The method is illustrated by the design of a Phase II clinical trial in head and neck cancer.

Statistics:

• The proposed trial design aims to evaluate objective response rates and stable disease rates in patients with cancer.
• The approach is applicable to experimental anticancer agents with both cytostatic and cytotoxic effects.
• The restricted search algorithm used to select the trial design evaluated several alternative hypotheses, ensuring that the selected design had sufficient statistical power.
• The trial design incorporates a 5% type I error constraint, which is a common constraint in clinical trials.

Sources:

• Kocherginsky, M., et al. (2009). Design of Phase II cancer trials for evaluation of cytostatic/cytotoxic agents. Journal of Biopharmaceutical Statistics, 19(3), 524-529.